EP1259487B8 - 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors - Google Patents
2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors Download PDFInfo
- Publication number
- EP1259487B8 EP1259487B8 EP01946854.5A EP01946854A EP1259487B8 EP 1259487 B8 EP1259487 B8 EP 1259487B8 EP 01946854 A EP01946854 A EP 01946854A EP 1259487 B8 EP1259487 B8 EP 1259487B8
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- mono
- amino
- nicotinamide derivatives
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09179064.2A EP2168948B1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0001930.7A GB0001930D0 (en) | 2000-01-27 | 2000-01-27 | Organic compounds |
GB0001930 | 2000-01-27 | ||
PCT/EP2001/000835 WO2001055114A1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09179064.2A Division-Into EP2168948B1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
EP09179064.2A Division EP2168948B1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1259487A1 EP1259487A1 (en) | 2002-11-27 |
EP1259487B1 EP1259487B1 (en) | 2009-12-23 |
EP1259487B8 true EP1259487B8 (en) | 2014-04-23 |
Family
ID=9884488
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01946854.5A Expired - Lifetime EP1259487B8 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
EP09179064.2A Expired - Lifetime EP2168948B1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09179064.2A Expired - Lifetime EP2168948B1 (en) | 2000-01-27 | 2001-01-25 | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
Country Status (25)
Country | Link |
---|---|
US (1) | US6624174B2 (en) |
EP (2) | EP1259487B8 (en) |
JP (1) | JP3894793B2 (en) |
KR (1) | KR100554988B1 (en) |
CN (1) | CN1216867C (en) |
AT (1) | ATE452880T1 (en) |
AU (1) | AU771626B2 (en) |
BR (1) | BR0107805A (en) |
CA (1) | CA2396590C (en) |
CZ (1) | CZ20022582A3 (en) |
DE (1) | DE60140860D1 (en) |
ES (2) | ES2338407T3 (en) |
GB (1) | GB0001930D0 (en) |
HK (1) | HK1050895A1 (en) |
HU (1) | HUP0204083A3 (en) |
IL (2) | IL150481A0 (en) |
MX (1) | MXPA02007319A (en) |
NO (1) | NO323826B1 (en) |
NZ (1) | NZ520005A (en) |
PL (1) | PL356307A1 (en) |
PT (2) | PT1259487E (en) |
RU (1) | RU2296124C2 (en) |
SK (1) | SK287426B6 (en) |
WO (1) | WO2001055114A1 (en) |
ZA (1) | ZA200205988B (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
US7419428B2 (en) * | 2000-04-28 | 2008-09-02 | Igt | Cashless transaction clearinghouse |
DE10023492A1 (en) * | 2000-05-09 | 2001-11-22 | Schering Ag | New 2-(((hetero)aryl-alkyl)-amino)-aza-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases |
PT1313734E (en) | 2000-09-01 | 2010-02-09 | Novartis Vaccines & Diagnostic | Aza heterocyclic derivatives and their therapeutic use |
EP1317442B1 (en) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
MXPA03010099A (en) * | 2001-05-08 | 2004-03-10 | Schering Ag | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3. |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
CN1671666A (en) * | 2002-07-31 | 2005-09-21 | 舍林股份公司 | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
JP4613130B2 (en) | 2002-08-23 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Benzimidazole quinolinones and their use |
US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
ES2527185T3 (en) | 2003-03-07 | 2015-01-21 | Santen Pharmaceutical Co., Ltd | New compounds that have a 4-pyridyl alkylthio group as a substituent |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
JP2007505938A (en) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Combination of VEGF receptor inhibitor and chemotherapeutic agent |
JP2007505939A (en) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Combinations of VEGF receptor inhibitors with other therapeutic agents |
US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
CA2543820C (en) | 2003-11-07 | 2012-07-10 | Chiron Corporation | Methods for synthesizing quinolinone compounds |
UA89035C2 (en) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Hydroxamic acid esters and pharmaceutical use thereof |
DK1717229T3 (en) | 2004-02-17 | 2011-09-19 | Santen Pharmaceutical Co Ltd | New cyclic compound with 4-pyridylalkylthio group with substituted amino (therein) substituted |
DE102004009238A1 (en) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
JPWO2006070878A1 (en) * | 2004-12-28 | 2008-06-12 | アステラス製薬株式会社 | Carboxylic acid derivative or salt thereof |
EP2410043A3 (en) | 2004-12-29 | 2013-01-23 | Hadasit Medical Research Services And Development Ltd. | Stem cells culture systems |
US8597947B2 (en) | 2004-12-29 | 2013-12-03 | Hadasit Medical Research Services & Development Limited | Undifferentiated stem cell culture systems |
DE602006016564D1 (en) * | 2005-03-03 | 2010-10-14 | Santen Pharmaceutical Co Ltd | NEW CYCLIC COMPOUND WITH CHINOLYL ALKYLTHIOGROUP |
ES2548729T3 (en) | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | New cyclic compound having pyrimidinylalkylthio group |
CN101223157B (en) | 2005-05-17 | 2013-03-06 | 诺瓦提斯公司 | Methods for synthesizing heterocyclic compounds |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
PL1957074T3 (en) | 2005-11-29 | 2014-08-29 | Novartis Ag | Formulations of quinolinones |
AR059066A1 (en) * | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
CA2676163A1 (en) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
ES2530370T5 (en) | 2007-04-18 | 2018-05-28 | Hadasit Medical Research Services & Development Limited | Retinal pigment epithelial cells derived from stem cells |
CN101918834B (en) * | 2008-01-07 | 2014-05-28 | 奥索临床诊断有限公司 | Calibrator/control for simultaneous assay of proteins capable of complexing with one another |
MX2010010505A (en) * | 2008-03-26 | 2010-10-26 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes. |
ES2445517T3 (en) | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Pyridine derivatives as inhibitors of VEGFR-2 receptor and protein tyrosine kinase |
CN101676267B (en) * | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-4-(1-cyan cyclopentyl) phenyl-2-(4-picolyl) amidogen-3-pyridinecarboxamide salt |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
HUE043536T2 (en) * | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | Heterocyclic compounds useful as pdk1 inhibitors |
EP2504339A1 (en) | 2009-11-25 | 2012-10-03 | Novartis AG | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
JP2013532149A (en) | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives |
JP2013528635A (en) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | Biphenyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives |
CN103492390A (en) | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | Fluorophenyl bicyclic heteroaryl compounds |
KR101412794B1 (en) * | 2011-07-27 | 2014-07-01 | 보령제약 주식회사 | New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug |
US20150099758A1 (en) * | 2012-05-08 | 2015-04-09 | Anvyl Llc | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof |
WO2015077845A1 (en) | 2013-11-28 | 2015-06-04 | Csl Limited | Method of treating nephropathy |
BR112016019161B1 (en) | 2014-02-21 | 2022-12-20 | Frost Biologic, Inc | ANTIMITOTIC AMIDES, PHARMACEUTICAL COMPOSITIONS INCLUDING THEM AND THEIR USE |
JP2018502575A (en) | 2014-12-30 | 2018-02-01 | セル キュア ニューロサイエンシズ リミテッド | Evaluation method of retinal pigment epithelial cell population |
JP6882981B2 (en) | 2014-12-30 | 2021-06-02 | セル キュア ニューロサイエンシズ リミテッド | RPE cell population and how to make it |
WO2017017686A1 (en) | 2015-07-29 | 2017-02-02 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
EP3331995A1 (en) | 2015-08-05 | 2018-06-13 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
EP4155391A1 (en) | 2015-08-05 | 2023-03-29 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
UA126372C2 (en) | 2015-08-31 | 2022-09-28 | Тон-А Сосіо Холдінгз Ко., Лтд. | Heteroaryl compounds and their use as therapeutic drugs |
AU2016347652A1 (en) | 2015-10-26 | 2018-05-24 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
IL269363B2 (en) | 2017-03-16 | 2024-02-01 | Lineage Cell Therapeutics Inc | Methods for measuring therapeutic effects of retinal disease therapies |
US12023353B2 (en) | 2017-10-18 | 2024-07-02 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
CN113038951B (en) | 2018-09-20 | 2024-04-30 | 耶达研究及发展有限公司 | Method for treating amyotrophic lateral sclerosis |
EP3754014A1 (en) | 2019-06-21 | 2020-12-23 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing retinal pigment epithelium cells |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
WO2022261320A1 (en) | 2021-06-09 | 2022-12-15 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating retinal diseases and conditions |
JP2024527986A (en) | 2021-07-28 | 2024-07-26 | リネージ セル セラピューティクス インコーポレイテッド | Retinal pigment epithelial cell proliferation |
WO2023211857A1 (en) | 2022-04-25 | 2023-11-02 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating vision loss |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE91128T1 (en) * | 1989-04-20 | 1993-07-15 | Boehringer Ingelheim Pharma | 5,11-DIHYDRO-6H-DIPYRIDO (3,2-B:2',3'-E>DIAZEPIN- 6-ONE AND ITS USE IN THE PREVENTION AND TREATMENT OF AIDS. |
ATE384062T1 (en) * | 1996-08-23 | 2008-02-15 | Novartis Pharma Gmbh | SUBSTITUTED PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF |
ID22781A (en) | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Nicotynamide derivatives |
WO1998057957A1 (en) | 1997-06-18 | 1998-12-23 | Nissan Chemical Industries, Ltd. | Pyridine compounds and herbicides |
AR013693A1 (en) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | NEW PIPERIDINES AND PIPERAZINAS AS INHIBITORS OF THE PLAQUETARY AGREGATION |
CA2332957A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
ATE326453T1 (en) | 1998-12-23 | 2006-06-15 | Lilly Co Eli | ANTITHRBOTIC AMIDES |
RU2260592C9 (en) * | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Cyclic inhibitors of protein-tyrosine kinases |
US6794397B2 (en) | 2000-01-27 | 2004-09-21 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
-
2000
- 2000-01-27 GB GBGB0001930.7A patent/GB0001930D0/en not_active Ceased
-
2001
- 2001-01-25 AU AU28499/01A patent/AU771626B2/en not_active Ceased
- 2001-01-25 EP EP01946854.5A patent/EP1259487B8/en not_active Expired - Lifetime
- 2001-01-25 PL PL01356307A patent/PL356307A1/en not_active Application Discontinuation
- 2001-01-25 MX MXPA02007319A patent/MXPA02007319A/en active IP Right Grant
- 2001-01-25 RU RU2002121645/15A patent/RU2296124C2/en not_active IP Right Cessation
- 2001-01-25 ES ES01946854T patent/ES2338407T3/en not_active Expired - Lifetime
- 2001-01-25 BR BR0107805-4A patent/BR0107805A/en not_active Application Discontinuation
- 2001-01-25 CZ CZ20022582A patent/CZ20022582A3/en unknown
- 2001-01-25 SK SK1085-2002A patent/SK287426B6/en not_active IP Right Cessation
- 2001-01-25 NZ NZ520005A patent/NZ520005A/en not_active IP Right Cessation
- 2001-01-25 DE DE60140860T patent/DE60140860D1/en not_active Expired - Lifetime
- 2001-01-25 ES ES09179064.2T patent/ES2490191T3/en not_active Expired - Lifetime
- 2001-01-25 PT PT01946854T patent/PT1259487E/en unknown
- 2001-01-25 CN CN018042333A patent/CN1216867C/en not_active Expired - Fee Related
- 2001-01-25 JP JP2001555056A patent/JP3894793B2/en not_active Expired - Lifetime
- 2001-01-25 IL IL15048101A patent/IL150481A0/en unknown
- 2001-01-25 PT PT91790642T patent/PT2168948E/en unknown
- 2001-01-25 CA CA2396590A patent/CA2396590C/en not_active Expired - Lifetime
- 2001-01-25 KR KR1020027009671A patent/KR100554988B1/en not_active IP Right Cessation
- 2001-01-25 WO PCT/EP2001/000835 patent/WO2001055114A1/en active IP Right Grant
- 2001-01-25 HU HU0204083A patent/HUP0204083A3/en unknown
- 2001-01-25 US US10/181,005 patent/US6624174B2/en not_active Expired - Lifetime
- 2001-01-25 AT AT01946854T patent/ATE452880T1/en active
- 2001-01-25 EP EP09179064.2A patent/EP2168948B1/en not_active Expired - Lifetime
-
2002
- 2002-06-27 IL IL150481A patent/IL150481A/en not_active IP Right Cessation
- 2002-07-02 NO NO20023218A patent/NO323826B1/en not_active IP Right Cessation
- 2002-07-26 ZA ZA200205988A patent/ZA200205988B/en unknown
-
2003
- 2003-04-29 HK HK03103030A patent/HK1050895A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
EP1396493A4 (en) | Heterocyclic compounds | |
AU4313797A (en) | Qinoline derivatives inhibiting the effect of growth factors such as vegf | |
MXPA01004256A (en) | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors. | |
NO20021401L (en) | Quinazoline compounds and pharmaceutical preparations containing such compounds | |
EP1369418A4 (en) | Quinazoline derivatives | |
ATE180468T1 (en) | ANTHRANILIC ACID DERIVATIVES | |
MX9804247A (en) | Quinazoline derivatives. | |
ATE311358T1 (en) | IMMUNO-REGULATING COMPOUNDS, THEIR DERIVATIVES AND THEIR USE | |
HUP0400246A2 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
PL350891A1 (en) | Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase | |
ATE126796T1 (en) | QUINAZOLINE DERIVATIVES AND THEIR PRODUCTION. | |
DE69720966D1 (en) | BENZO [C] CHINOLIZINE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS 5-ALFA REDUCTASE INHIBITORS | |
NZ517315A (en) | New derivatives of A-500359 | |
IE890293L (en) | Quinolone derivatives | |
WO2000075158A3 (en) | NOVEL 6-PHENYLPURINE 9-β-D-RIBONUCLEOSIDES WITH ANTINEOPLASTIC ACTIVITY, THEIR USE FOR PREPARING PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS | |
CA2239053A1 (en) | Diphenyl pyridyl ethane derivatives as pde iv inhibitors | |
MX2008002753A (en) | Pyridazinone derivatives used for the treatment of pain. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020705 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO PAYMENT 20020705;SI PAYMENT 20020705 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVARTIS AG Owner name: NOVARTIS PHARMA GMBH |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVARTIS PHARMA GMBH Owner name: NOVARTIS AG |
|
17Q | First examination report despatched |
Effective date: 20081215 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60140860 Country of ref document: DE Date of ref document: 20100204 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20100319 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20100400668 Country of ref document: GR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2338407 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100125 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100125 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: NOVARTIS AG |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20191230 Year of fee payment: 20 Ref country code: GR Payment date: 20191227 Year of fee payment: 20 Ref country code: BE Payment date: 20191227 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20200122 Year of fee payment: 20 Ref country code: ES Payment date: 20200203 Year of fee payment: 20 Ref country code: GB Payment date: 20200115 Year of fee payment: 20 Ref country code: IT Payment date: 20200114 Year of fee payment: 20 Ref country code: NL Payment date: 20200130 Year of fee payment: 20 Ref country code: AT Payment date: 20191227 Year of fee payment: 20 Ref country code: DE Payment date: 20200114 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20200116 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20200123 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60140860 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20210124 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20210124 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 452880 Country of ref document: AT Kind code of ref document: T Effective date: 20210125 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20210125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210124 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210204 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210126 |